- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Marconi HCP appoints prez, cuts new deals
Louis H. (Larry) Miller has been promoted to president of Marconi Health Care Products. Miller, who was previously vice president and general manager of HCP, has become only the third president in HCP’s history. Miller will emphasize e-business
Louis H. (Larry) Miller has been promoted to president of Marconi Health Care Products. Miller, who was previously vice president and general manager of HCP, has become only the third president in HCP’s history. Miller will emphasize e-business initiatives revolving around the imaging distributor’s Web site, marconihcp.com.
In other news, HCP has signed a three-year agreement with Broadlane, which specializes in the delivery of supply chain services to the healthcare industry. The contract extends an existing contract and contains two one-year renewal options. The deal is potentially worth more than $30 million in annual sales. HCP has also entered into a relationship with Deus Technologies to distribute that company’s Rapid-Screen RS-2000. The system uses computer-aided detection to identify regions possibly associated with early-stage lung cancer.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
